Recently, listed pharmaceutical companies have released their 2021 performance express. According to Hithink Royalflush Information Network Co.Ltd(300033) data, as of March 2, 126 A-share Biopharmaceutical Enterprises had released relevant data, and the net profit of 94 had increased compared with the same period last year. Among them, Beijing Hotgen Biotech Co.Ltd(688068) net profit increased by 185681%, and Chongqing Zhifei Biological Products Co.Ltd(300122) net profit reached 10.197 billion yuan. Among the loss making enterprises, Baiji Shenzhou has the highest loss, with a loss of about 9.748 billion yuan.
Beijing Hotgen Biotech Co.Ltd(688068) net profit increased the most, while Chongqing Zhifei Biological Products Co.Ltd(300122) net profit increased the most
In the performance express disclosed by 126 A-share Biopharmaceutical Enterprises, Beijing Hotgen Biotech Co.Ltd(688068) net profit increased the most. On February 28, Beijing Hotgen Biotech Co.Ltd(688068) released the performance express for 2021. During the reporting period, the revenue reached 5.372 billion yuan, a year-on-year increase of 946.14%; The net profit attributable to the owners of the parent company was 2.193 billion yuan, a year-on-year increase of 185681%.
Beijing Hotgen Biotech Co.Ltd(688068) the substantial increase in performance is related to the substantial increase in the income of overseas covid-19 antigen testing products. In early 2021, the New Coronavirus Beijing Hotgen Biotech Co.Ltd(688068) antigen detection kit (anterior nasal cavity) and the New Coronavirus 2019n-CoV antigen detection kit (saliva) were developed by the New Coronavirus, and the two rapid test reagent products of New Coronavirus antigen were obtained from the German Federal medicines and treatment equipment Research Institute (BfArM) for home free testing. Led to the explosive growth of the company’s foreign trade orders in the first half of the year; In the second half of this year, Beijing Hotgen Biotech Co.Ltd(688068) ‘s self testing products developed by New Coronavirus were self testing registration / filing of the major EU economies, including CE and MHRA, France ANSM and other major economies. The fourth quarter was affected by the variation of COVID-19 virus Delta and the Olympic Games.
In addition, among the A-share Biopharmaceutical Enterprises that have disclosed their performance, Chongqing Zhifei Biological Products Co.Ltd(300122) net profit is the highest. Its 2021 annual performance express shows that during the reporting period, the company achieved an operating revenue of 30.637 billion yuan, a year-on-year increase of 101.68%; In 2021, the net profit was 10.197 billion yuan, with a year-on-year increase of 208.88%. Chongqing Zhifei Biological Products Co.Ltd(300122) is the only pharmaceutical enterprise with a net profit of more than 10 billion among the pharmaceutical enterprises that disclosed the performance express.
Chongqing Zhifei Biological Products Co.Ltd(300122) disclosed that the main reason for the increase of the company’s net profit was that during the reporting period, the company continued to focus on the business development objectives, increased R & D investment, pushed through the old and brought forth the new, continued to steadily improve the sales of independent products and agency products, and the company’s main business income, net profit and other important financial indicators increased significantly compared with the same period of last year.
The reporter of Beijing News inquired about the semi annual report of Chongqing Zhifei Biological Products Co.Ltd(300122) 2021 and found that the vaccine products of Chongqing Zhifei Biological Products Co.Ltd(300122) have contributed a lot to the growth of its net profit. According to the semi annual report of 2021, the revenue of vaccine products reached 13.154 billion yuan. It is reported that in March 1, 2021, Chongqing Zhifei Biological Products Co.Ltd(300122) ‘s recombinant New Coronavirus vaccine (CHO cell) was registered in Uzbekistan and became the first international registered subunit COVID-19 vaccine. Approved for emergency use in China on March 10, 2021; On February 21 this year, the vaccine was approved as a sequential (heterologous) booster vaccine of covid-19 inactivated vaccine in China.
In addition to the Beijing Hotgen Biotech Co.Ltd(688068) \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ achieve turnaround.
R & D investment is large, and Baiji Shenzhou has a loss of nearly 10 billion
On February 28, Baiji Shenzhou released its 2021 annual performance express. During the reporting period, Baiji Shenzhou achieved a total operating revenue of 7.589 billion yuan, an increase of 257.9% over the same period of last year; The net profit loss attributable to the owners of the parent company was about 9.748 billion yuan.
On December 15, 2021, Baiji Shenzhou landed on the science and innovation board, becoming China’s first global pharmaceutical and biological company listed on Nasdaq, HKEx and Shanghai Stock Exchange. It is understood that Baiji Shenzhou has been in a state of loss for nearly five years. The annual report shows that from 2018 to 2021, Baiji Shenzhou lost 4.747 billion yuan, 6.915 billion yuan, 11.384 billion yuan and 9.748 billion yuan respectively. In terms of R & D, the total R & D investment of Baiji Shenzhou in 2020 was about 8.9 billion yuan, and the R & D expenditure in the first three quarters of 2021 was about 6.52 billion yuan.
In the field of key products, in 2021, the global sales of BTK inhibitor Baiyue Ze (zebutinib capsule) totaled 1.406 billion yuan, compared with 286 million yuan in the same period of last year; The sales of baizean (tirelizumab injection) in China totaled 1.647 billion yuan, and the sales in the Chinese market totaled 1.118 billion yuan in the same period of last year.
Baiji Shenzhou disclosed that in 2021, the company’s China commercialization team continued to make efforts to bring new products to the market. In 2021, baihuize (pamipali capsule), a newly launched and independently developed product, is aimed at treating patients with recurrent advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer with germline BRCA (gbrca) mutation who have previously received second-line or more chemotherapy. Baihuize has been included in the national medical insurance catalogue (2021). The national medical insurance catalogue (2021) has been officially implemented since January 1, 2022. Triamcinolone acetonide for injection (triamcinolone acetonide) and triamcinolone acetonide for injection β Injection), savinco (rituximab for injection) and pubeshi (bevacizumab injection biological analogue). At present, Baiji Shenzhou has commercialized a total of 11 products in China, of which 8 are authorized products. These products may bring a turnaround for Baiji Shenzhou’s future performance.
In addition to Baiji Shenzhou, enterprises with high losses include Sinocelltech Group Limited(688520) , Maiwei biology, Hunan Nucien Pharmaceutical Co.Ltd(688189) , Sino Medical Sciences Technology Inc(688108) , Frontier Biotechnologies Inc(688221) , Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) , etc.
